- Home
- BKYI vs MBIO Comparison
BKYI vs MBIO Comparison
Compare BKYI & MBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BKYI
- MBIO
- Stock Information
- Founded
- BKYI 1993
- MBIO 2015
- Country
- BKYI United States
- MBIO United States
- Employees
- BKYI N/A
- MBIO N/A
- Industry
- BKYI Computer Software: Prepackaged Software
- MBIO Biotechnology: Pharmaceutical Preparations
- Sector
- BKYI Technology
- MBIO Health Care
- Exchange
- BKYI Nasdaq
- MBIO Nasdaq
- Market Cap
- BKYI 4.8M
- MBIO 4.7M
- IPO Year
- BKYI 1997
- MBIO N/A
- Fundamental
- Price
- BKYI $0.76
- MBIO $1.61
- Analyst Decision
- BKYI
- MBIO
- Analyst Count
- BKYI 0
- MBIO 0
- Target Price
- BKYI N/A
- MBIO N/A
- AVG Volume (30 Days)
- BKYI 103.2K
- MBIO 117.8K
- Earning Date
- BKYI 11-13-2025
- MBIO 11-07-2025
- Dividend Yield
- BKYI N/A
- MBIO N/A
- EPS Growth
- BKYI N/A
- MBIO N/A
- EPS
- BKYI N/A
- MBIO N/A
- Revenue
- BKYI $6,911,148.00
- MBIO N/A
- Revenue This Year
- BKYI $7.45
- MBIO N/A
- Revenue Next Year
- BKYI $23.29
- MBIO N/A
- P/E Ratio
- BKYI N/A
- MBIO N/A
- Revenue Growth
- BKYI N/A
- MBIO N/A
- 52 Week Low
- BKYI $0.52
- MBIO $0.89
- 52 Week High
- BKYI $3.68
- MBIO $21.95
- Technical
- Relative Strength Index (RSI)
- BKYI 48.39
- MBIO 51.87
- Support Level
- BKYI $0.73
- MBIO $1.54
- Resistance Level
- BKYI $0.78
- MBIO $1.64
- Average True Range (ATR)
- BKYI 0.04
- MBIO 0.09
- MACD
- BKYI 0.01
- MBIO 0.02
- Stochastic Oscillator
- BKYI 33.73
- MBIO 81.52
About BKYI BIO-key International Inc.
BIO-key International Inc is a fingerprint biometric technology company. It develops and markets fingerprint biometric identification and identity verification technologies, as well as related identity management and credentialing hardware and software solutions. Its product portfolio comprises SideSwipe, SidePass, EcoID, WEB-key, and others. The company generates its revenue in the form of Services, License fees, and others.
About MBIO Mustang Bio Inc.
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.